Sudden Cardiac DeathTIDENCT00748111
Thrombus and Inflammation Study in Sudden Cardiac DEath
A study testing Blood sample in people with Sudden Cardiac Death and Acute Myocardial Infarction, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 300.000 in the United States. Despite community-based interventions, overall survival remains below 5%. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Sudden Cardiac Death, Acute Myocardial Infarction
- What is being tested?
- Blood sample
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 380 participants
- Where
- 1 siteFrance
- Study dates
- Aug 2008to Dec 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with sudden cardiac death without coronary artery occlusion
- Patients with acute myocardial infarction due to coronary artery occlusion
- Patients with stable angina treated with coronary angioplasty
- Written informed consent
- Social security
Who cannot join
- Pregnancy
- Small arteries that preclude the use of aspiration devices
- Sudden death without coronary lesions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Thrombus and Inflammation in Sudden Cardiac DEath
Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 300.000 in the United States. Despite community-based interventions, overall survival remains below 5%. Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths. Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies. However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear. In particular, coronary artery occlusion can be rapidly followed by chest pain, which acts as a signal and allows identification of patients for emergency reperfusion. However, in some cases, the coronary artery occlusion is followed by a sudden onset of arrhythmia and sudden death. Recent data suggest that acute coronary occlusion is caused by plaque erosion or rupture and is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. During angioplasty procedures, coronary artery thrombus are aspirated, providing the opportunity for pathological studies. The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia.
Read the detailed description
Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 40 000 deaths in France and 300.000 in the United States.(1) Despite community-based interventions, overall survival remains below 5%. (2) Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. (3)The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. (4) Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths and hypertrophic and dilated cardiomyopathies account for another 10 to 15% of cardiac causes.(4,5) Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies.(6-10) However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear.The Framingham study reported that sudden death occurred without prior manifestations of coronary heart disease in more than 50% of men and 65% of women. (11) Data from 10 countries from WHO MONICA PROJECT show that sudden deaths are more frequent than non sudden coronary deaths until age 60. (figure). In a study on the value of immediate coronary angiography and angioplasty in survivors of SCD, a recent coronary artery occlusion was found in over 50% of patients and unstable coronary artery lesions in 20% (12). In two series based on autopsies, the rate of coronary artery lesions in non-survivors of SCD was over 80% (13-15). In a study based on autopsies of non-survivors of SCD, fresh thrombus was found in a majority of cases. (2)Furthermore, noninflammatory plaque erosion was found as an underlying cause to thrombus formation in 40% of cases (14). In this case, thrombus is formed on a denuded endothelial plaque surface and is in direct contact with activated smooth muscle cells. In 211 patients with non-complicated acute myocardial infarction caused by acute coronary occlusion, SASKIA et al studied the age of intracoronary thrombi, aspirated during angioplasty (16). In at least 50% of patients, thrombi were days or weeks old, thereby suggesting ischemic pre-conditioning in this sub-group of acute myocardial infarction patients with no ventricular arrhythmia. Maier et al studied intra-coronary concentrations of selected inflammatory biomarkers in 42 patients with acute myocardial infarction (17). High levels of interleukin 6 and serum amyloid A were found at the occlusion site; and these levels were even higher in patients with no previous clinical symptoms before the acute myocardial infarction. These data suggest that plaque erosion or rupture is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. We also believe that a precise determination of endothelial cell apoptosis, plaque erosion, and systemic and local inflammation could shed light on the pathogenic mechanisms prevailing in SCD due to acute coronary artery occlusion. Protection and thrombectomy devices were recently developed to avoid distal embolisation during angioplasty procedures in saphenous vein graphs or during angioplasty for acute myocardial infarction. These devices provide the unique opportunity to harvest blood and thrombi from the site of coronary occlusion. The aspirate can be used to study the speed and the intensity of local thrombus formation. The use of such techniques could be extended to patients with a SCD due to an acute coronary artery occlusion and the data compared to that of patients with an acute myocardial infarction without ventricular arrhythmia. Furthermore, markers of endothelial cell apoptosis, local and systemic inflammatory biomarkers in the culprit coronary artery and in the systemic blood could be studied in such patients and also during angioplasty procedures performed in patients with stable coronary lesions.(18-23) The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia. Furthermore, coronary artery and systemic blood samples will be drawn in both groups and before coronary angioplasty procedures in patients with stable angina pectoris to determine the role of local and systemic inflammation and endothelial cell apoptosis in these settings.
- Conditions
- Sudden Cardiac Death, Acute Myocardial Infarction
- Being tested
- Blood sample
- Keywords
- Sudden death, Out of hospital cardiac arrest, Acute myocardial infarction, Acute coronary syndrome
- Medical subject headings
- Death, Sudden, Cardiac, Death, Sudden, Out-of-Hospital Cardiac Arrest, Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleOther
Blood sample and thrombus sample
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Sudden cardiac death hospitalized Receives: Other: Blood sample |
| 2 | Experimental | Acute myocardial infarction Receives: Other: Blood sample |
| 3 | Experimental | Angioplasty procedures programmed Receives: Other: Blood sample |
| 4 | Experimental | Sudden cardiac death hospitalized without coronary syndrome Receives: Other: Blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Age of thrombus collected at the site of acute coronary occlusion.
Measured: one day
Secondary outcomes (1)
Local and systemic inflammation and endothelial cell apoptosis in patients with sudden death due to acute coronary occlusion, acute myocardial infarction and stable angina treated with coronary angioplasty.
Measured: one day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2008 (estimated)
- Study startAug 2008
- Primary completionApr 2012
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sudden Cardiac DeathStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 380 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France, URC-CIC Paris Descartes Necker Cochin
- Responsible party
- Sponsor
- Investigators
- Xavier JOUVEN, MD, Principal investigator, Institut National de la Santé Et de la Recherche Médicale, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00748111
- Sponsor's protocol ID
- P080201
- Acronym
- TIDE
- Status last verified
- Feb 2026
- First submitted
- 31 Jul 2008
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Empana JP, Boulanger CM, Tafflet M, Renard JM, Leroyer AS, Varenne O, Prugger C, Silvain J, Tedgui A, Cariou A, Montalescot G, Jouven X, Spaulding C. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):28-36. doi: 10.1177/2048872614538404. Epub 2014 Jun 9.
PubMed 24912925
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thrombus and Inflammation in Sudden Cardiac DEath
- ClinicalTrials.gov ID
- NCT00748111
- Acronym / sponsor ID
- TIDE / P080201
- Conditions
- Sudden Cardiac Death, Acute Myocardial Infarction
- Keywords
- Sudden death, Out of hospital cardiac arrest, Acute myocardial infarction, Acute coronary syndrome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 380 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France, URC-CIC Paris Descartes Necker Cochin
- Study start
- Aug 2008
- Primary completion
- Apr 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 8 Sep 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 300.000 in the United States. Despite community-based interventions, overall survival remains below 5%. Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths. Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies. However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear. In particular, coronary artery occlusion can be rapidly followed by chest pain, which acts as a signal and allows identification of patients for emergency reperfusion. However, in some cases, the coronary artery occlusion is followed by a sudden onset of arrhythmia and sudden death. Recent data suggest that acute coronary occlusion is caused by plaque erosion or rupture and is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. During angioplasty procedures, coronary artery thrombus are aspirated, providing the opportunity for pathological studies. The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia.
Detailed description
Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 40 000 deaths in France and 300.000 in the United States.(1) Despite community-based interventions, overall survival remains below 5%. (2) Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. (3)The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. (4) Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths and hypertrophic and dilated cardiomyopathies account for another 10 to 15% of cardiac causes.(4,5) Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies.(6-10) However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear.The Framingham study reported that sudden death occurred without prior manifestations of coronary heart disease in more than 50% of men and 65% of women. (11) Data from 10 countries from WHO MONICA PROJECT show that sudden deaths are more frequent than non sudden coronary deaths until age 60. (figure). In a study on the value of immediate coronary angiography and angioplasty in survivors of SCD, a recent coronary artery occlusion was found in over 50% of patients and unstable coronary artery lesions in 20% (12). In two series based on autopsies, the rate of coronary artery lesions in non-survivors of SCD was over 80% (13-15). In a study based on autopsies of non-survivors of SCD, fresh thrombus was found in a majority of cases. (2)Furthermore, noninflammatory plaque erosion was found as an underlying cause to thrombus formation in 40% of cases (14). In this case, thrombus is formed on a denuded endothelial plaque surface and is in direct contact with activated smooth muscle cells. In 211 patients with non-complicated acute myocardial infarction caused by acute coronary occlusion, SASKIA et al studied the age of intracoronary thrombi, aspirated during angioplasty (16). In at least 50% of patients, thrombi were days or weeks old, thereby suggesting ischemic pre-conditioning in this sub-group of acute myocardial infarction patients with no ventricular arrhythmia. Maier et al studied intra-coronary concentrations of selected inflammatory biomarkers in 42 patients with acute myocardial infarction (17). High levels of interleukin 6 and serum amyloid A were found at the occlusion site; and these levels were even higher in patients with no previous clinical symptoms before the acute myocardial infarction. These data suggest that plaque erosion or rupture is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. We also believe that a precise determination of endothelial cell apoptosis, plaque erosion, and systemic and local inflammation could shed light on the pathogenic mechanisms prevailing in SCD due to acute coronary artery occlusion. Protection and thrombectomy devices were recently developed to avoid distal embolisation during angioplasty procedures in saphenous vein graphs or during angioplasty for acute myocardial infarction. These devices provide the unique opportunity to harvest blood and thrombi from the site of coronary occlusion. The aspirate can be used to study the speed and the intensity of local thrombus formation. The use of such techniques could be extended to patients with a SCD due to an acute coronary artery occlusion and the data compared to that of patients with an acute myocardial infarction without ventricular arrhythmia. Furthermore, markers of endothelial cell apoptosis, local and systemic inflammatory biomarkers in the culprit coronary artery and in the systemic blood could be studied in such patients and also during angioplasty procedures performed in patients with stable coronary lesions.(18-23) The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia. Furthermore, coronary artery and systemic blood samples will be drawn in both groups and before coronary angioplasty procedures in patients with stable angina pectoris to determine the role of local and systemic inflammation and endothelial cell apoptosis in these settings.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Other: Blood sampleSudden cardiac death hospitalized |
| 2 | Experimental | Other: Blood sampleAcute myocardial infarction |
| 3 | Experimental | Other: Blood sampleAngioplasty procedures programmed |
| 4 | Experimental | Other: Blood sampleSudden cardiac death hospitalized without coronary syndrome |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients with sudden cardiac death without coronary artery occlusion
- Patients with acute myocardial infarction due to coronary artery occlusion
- Patients with stable angina treated with coronary angioplasty
- Written informed consent
- Social security
Key exclusion criteria (3 listed)
- Pregnancy
- Small arteries that preclude the use of aspiration devices
- Sudden death without coronary lesions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampleBlood sample and thrombus sample | Other | 1, 2, 3, 4 |
Primary outcome
Age of thrombus collected at the site of acute coronary occlusion.
Time frame: one day
1 secondary outcome
Local and systemic inflammation and endothelial cell apoptosis in patients with sudden death due to acute coronary occlusion, acute myocardial infarction and stable angina treated with coronary angioplasty.
Time frame: one day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Results publication: PubMed 24912925Empana JP, Boulanger CM, Tafflet M, Renard JM, Leroyer AS, Varenne O, Prugger C, Silvain J, Tedgui A, Cariou A, Montalescot G, Jouven X, Spaulding C. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):28-36. doi: 10.1177/2048872614538404. Epub 2014 Jun 9.
Related trials for Sudden Cardiac Death
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Recruiting
Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy
Epilepsy, Hypothalamus
Not yet recruitingObservational study
Cardiovascular Pre-participation Screening in Children and Adolescents
Sudden Cardiac Death, Cardiac Arrhythmias
Recruiting
Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta
AAOCA, ACAOS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xavier JOUVEN, MD principal investigator
Institut National de la Santé Et de la Recherche Médicale, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample in people with Sudden Cardiac Death and Acute Myocardial Infarction, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Age of thrombus collected at the site of acute coronary occlusion. (time frame: one day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00748111, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.